Statistics for Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study

Total visits

views
Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study 3

Total visits per month

views
octubre 2024 0
noviembre 2024 0
diciembre 2024 0
enero 2025 0
febrero 2025 0
marzo 2025 0
abril 2025 0

File Visits

views
10.7448IAS.20.01.21678.pdf 2